IAN F. SMITH - 08 Oct 2025 Form 4 Insider Report for Stoke Therapeutics, Inc. (STOK)

Role
Chief Executive Officer, Director
Signature
/s/ Jonathan Allan, Attorney-in-Fact
Issuer symbol
STOK
Transactions as of
08 Oct 2025
Transactions value $
$0
Form type
4
Filing time
14 Oct 2025, 16:16:10 UTC
Previous filing
07 Oct 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
SMITH IAN F Chief Executive Officer, Director C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVENUE, BEDFORD /s/ Jonathan Allan, Attorney-in-Fact 14 Oct 2025 0001197032

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction STOK Stock Option (Right to Buy) Award $0 +570K $0.00 570K 08 Oct 2025 Common Stock 570K $30.50 Direct F1
transaction STOK Restricted Stock Units Award $0 +380K $0.00 380K 08 Oct 2025 Common Stock 380K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option shall vest as to 1/4 of the total award on October 6, 2026, with an additional 1/48 of the total award vesting monthly thereafter, subject to the reporting person's continued service to the Issuer on each vesting date.
F2 Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
F3 The award shall vest as to 1/4 of the total award annually on the sixth calendar day of October, subject to the reporting person's continued service to the Issuer on each vesting date, with the first tranche vesting on October 6, 2026.